Literature DB >> 2644145

Effects of dietary treatment on serum insulin and proinsulin response in newly diagnosed NIDDM.

N Yoshioka1, T Kuzuya, A Matsuda, Y Iwamoto.   

Abstract

Serum proinsulin is disproportionately elevated both in the basal state and after an oral glucose load in non-insulin-dependent diabetes mellitus (NIDDM). However, there is no detailed information about the effect of glycemic control on this abnormality. We investigated the effect of glycemic control by dietary treatment on serum proinsulin level in the basal state and in response to an oral glucose load. Ten NIDDM patients (7 men and 3 women), aged 19-60 yr, with mean (+/- SD) body mass index of 28 +/- 6 kg/m2 (range 21-42 kg/m2) and normal renal and liver function were studied. Before and after dietary therapy (25-30 kcal/kg ideal body wt), 100-g oral glucose tolerance tests were performed. Proinsulin was measured with our proinsulin-specific antiserum, which recognizes the connecting site of the B-chain of insulin and C-peptide. After dietary treatment, fasting plasma glucose decreased from 197 +/- 35 to 113 +/- 18 mg/dl (P less than .001). Both serum insulin and proinsulin decreased (insulin from 15 +/- 8 to 10 +/- 4 microU/ml, P less than .02; proinsulin from 31 +/- 18 to 13 +/- 5 pM, P less than .02), and the molar ratio of proinsulin to insulin also tended to decrease (from 0.321 +/- 0.08 to 0.24 +/- 0.10, P less than .10). Insulin response to oral glucose increased after dietary treatment, whereas proinsulin response did not change, resulting in a significant decrease in the molar ratio of the area under the curve of proinsulin to insulin after glucose load (from 0.28 +/- 0.12 to 0.13 +/- 0.07, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2644145     DOI: 10.2337/diab.38.2.262

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  8 in total

1.  Improvement in severe insulin resistance with frequent injections of lispro insulin.

Authors:  C H Raine; M J Krzyston; M Amr; L Hydrick
Journal:  J Natl Med Assoc       Date:  1999-07       Impact factor: 1.798

2.  Non-alcoholic fatty liver disease and impaired proinsulin conversion as newly identified predictors of the long-term non-response to a lifestyle intervention for diabetes prevention: results from the TULIP study.

Authors:  Vera Schmid; Robert Wagner; Corinna Sailer; Louise Fritsche; Konstantinos Kantartzis; Andreas Peter; Martin Heni; Hans-Ulrich Häring; Norbert Stefan; Andreas Fritsche
Journal:  Diabetologia       Date:  2017-08-24       Impact factor: 10.122

3.  A 10-year experience with 290 pancreas transplants at a single institution.

Authors:  D E Sutherland; D L Dunn; F C Goetz; W Kennedy; R C Ramsay; M W Steffes; S M Mauer; R Gruessner; K C Moudry-Munns; P Morel
Journal:  Ann Surg       Date:  1989-09       Impact factor: 12.969

4.  Clinical and Laboratory Evaluation of a New Specific Point-of-Care Test for Intact Proinsulin.

Authors:  Andreas Pfützner; Anke H Pfützner; Peter H Kann; Gunther Burgard
Journal:  J Diabetes Sci Technol       Date:  2016-09-25

5.  Effect of protein intake on glycaemic control and renal function in type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  J Pomerleau; M Verdy; D R Garrel; M H Nadeau
Journal:  Diabetologia       Date:  1993-09       Impact factor: 10.122

6.  Immunoradiometric assay of insulin, intact proinsulin and 32-33 split proinsulin and radioimmunoassay of insulin in diet-treated type 2 (non-insulin-dependent) diabetic subjects.

Authors:  P M Clark; J C Levy; L Cox; M Burnett; R C Turner; C N Hales
Journal:  Diabetologia       Date:  1992-05       Impact factor: 10.122

7.  Hyperinsulinaemia in obesity is not accompanied by an increase in serum proinsulin/insulin ratio in groups of human subjects with and without glucose intolerance.

Authors:  I Shiraishi; Y Iwamoto; T Kuzuya; A Matsuda; S Kumakura
Journal:  Diabetologia       Date:  1991-10       Impact factor: 10.122

Review 8.  Dietary advice for treatment of type 2 diabetes mellitus in adults.

Authors:  L Nield; H J Moore; L Hooper; J K Cruickshank; A Vyas; V Whittaker; C D Summerbell
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.